EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine
PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic PreparednessInnovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.
- PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic PreparednessInnovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.
- EpiVax will be carrying out the vaccine epitope selection portion of the collaboration using their comprehensive in silico vaccine design toolkit "iVAX" .
- In addition to vaccine epitope selection, EpiVax will also develop multiple designs, and will validate these in silico constructs in vivo with HLA-transgenic mice.
- EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design.